In Volume 10, Number 4 (August 2020) of the journal, the article “Assessing the Impact of Limited Distribution Drug Networks Based on Time to Accessing Oral Oncolytic Agents at an Integrated Specialty Pharmacy,” by Wyatt et al, contained an error in Figure 2 on page 203. The limited-distribution drugs and the non–limited-distribution drugs graphs were labeled incorrectly, showing the wrong color for the 2 categories. The Figure has been corrected in the article online.
In Volume 11, Number 1 (February 2021) of the journal, the article “Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan,” by Ekinci et al, contained an error on page 38. The last part of the sentence ending with “the longstanding practice had been to use empirically the FOD regimen in such patients, and use dexamethasone only on day 1 post-HSCT,” should have read “the longstanding practice had been to use empirically the FOD regimen in such patients.” This error has been corrected in the article online.